ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

AKT1 E17K Inhibitor ATV-1601

Also written as “ATV-1601” and “ATV-1601 + Fulvestrant”.

Its studies are mostly in Telangiectasia, Hereditary Hemorrhagic · Triple Negative Breast Neoplasms, led by Atavistik Bio.

Furthest: phase 2, since May 12, 20262 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Atavistik Bio22 open or runningphase 2since May 12, 2026Jun 18, 2025Dec 2027phase 2 · NCT07601425

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 18, 2025First study: phase 1 study in Breast NeoplasmsFirst studyNCT07038369 · 134 enrolled · United States, France, Singapore and more
  2. May 12, 2026Phase 2 study in Telangiectasia, Hereditary HemorrhagicPhase 2 reachedNCT07601425 · 100 planned · United States, Argentina

Ahead

  1. Dec 2027Primary completion: phase 2 study in Telangiectasia, Hereditary HemorrhagicNCT07601425
  2. Aug 31, 2028Primary completion: phase 1 study in Breast NeoplasmsNCT07038369

TargetBeta

AKT1 →read by rule
“An orally bioavailable non-covalent allosteric inhibitor of the serine/threonine protein kinase AKT (protein kinase B; v-akt murine thymoma viral oncogene homolog 1) isoform 1 mutation AKT1 E17K, ”NCIt, by rule

Other programs on AKT1

ProgramCompanyFurthest phaseStudies
capivasertibruleAstraZenecaphase 323

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07601425Telangiectasia, Hereditary Hemorrhagic · United States, Argentina2RecruitingDec 2027100
NCT07038369Breast Neoplasms · United States, France, Singapore and more1Active, not recruitingAug 31, 2028134

How it is read

Names in the registry

  • “ATV-1601”, 2 entries
  • “ATV-1601 + Fulvestrant”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.